We would love to hear your thoughts about our site and services, please take our survey here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Hi SOG - yes, I don't think the GSK lawyers have too much to worry about but litigation does seem to be a popular sport in the US.
Anyway, it'll be interesting to see what GSK does next re aquisitions. From the article Celtic and I linked to last evening, "Chris Sheldon, who has been at AstraZeneca for nearly two decades, will join GSK as a senior vice president, leading the commercial aspects of its business development, the company said in an emailed response to queries Wednesday.
He will identify late-stage deal opportunities and work with the research and development team to execute transactions, according to the statement, which confirmed an earlier Bloomberg News report. Garrett Rhyasen has also started at GSK this month as vice president of oncology search and evaluation, the company said.
“These appointments support our clear ambition to invest in our commercial capabilities to deliver future growth,” GSK said in the statement. “In addition to in-house development, GSK is committed to leveraging business development as a tool to secure access to external innovation, help shape the portfolio and further strengthen our late-stage pipeline.”
and
"Turmoil in the biotech sector could create opportunities for large pharmaceutical companies, and GSK is among drugmakers that appear to be most in need of deals, analysts at Bloomberg Intelligence wrote Wednesday.
“Mid-to-late stage pipeline assets would be welcomed at GSK, where growth seems tilted toward vaccines,” according to the BI note."
So from the above do we think it's a bit early for GSK to target SAR or are we a 'special case'?
Hbd. yes many of the opinion that SRA737 been down played by GSK.
But take into consideration that Sierra been dragging their heels, concentrating all their resources on momo. SRA737 sat virtually stagnant. A target price was set at 55 dollars a share for the Sierra shares and this is what GSK offered. It was those that set the target price that in effect have given this value to the Sierra pipeline. Sierra picked up momo which failed a phase 3 trial for a few million upfront. That was all it was worth at that time. Sierra have done sterling work with momo.
GSK i believe have nothing to answer for. The buyout was agreed by the majority of shareholders.
Regards
I reckon Aber if that were the outcome we would see a around a pound a share pre consolidation price. Circa market cap of 3 billion is not out of the question.
if all continues well on SRA737 alone, just prior to commercialisation should put us around the 400 million market cap.
Just my thoughts of ball park figure and there are others on here far more knowledgeable than me who can give a more reasoned case for a figure.
A while away and exactly how far, well who knows?
Be good also for those here that bought at a peak to get a decent return. They deserve it too.
Regards
As stated by someone yesterday, if GSK were to push 737 into market we could expect significant royalties .... so rather than GSK buying out the portion of rights to 737 owned by SAR, which could amount to a significant value based on projected possible sales, it would make more sense for GSK to simply buy out SAR as then not only do they negate the royalty payments to SAR but they also get the rest (TYK2, SKIL, FLT3 and TM/JR knowledge and experience)
That would be my wish ... GLALTHERS
I wonder if the various US lawsuits claiming Sierra shareholders have been fleeced on the GSK deal could mean GSK might wait until they've all been swatted away by their lawyers before they announce any big numbers for 737.
If GSK said 737 will be worth bazillions then that would only confirm the lawsuits have a point.
I'm beginning to think GSK might just quietly ensure the funding is there to take 737 all the way without much public mention of the market value.
Now if only we had a man on the inside....
Laz, I am not sure if what you have just said falls in to oxymoron territory or a paradox, either way the opposition of ideas or eventualities falls into my like box, as I would take this as significantly likely. Some blue sky ahead for all of us :) GLA
Whatever GSK/Sierra do with SRA737 from here it should have a material effect on our sp. The milestone payments and future royalties for 737 alone more than cover our current market cap meaning everything else would be worthless. Obviously, that would be nonsense with everything else that is progressing even if you remove the speculation of a T/O.
Sit on those hands - we have a winner.
Couldn't resist another top up at 201.9 ..... Hope my gut feeling is right ... roll on next week ; GLALTHERS
Yes I had forgotten the confirmation date ... So no red dot today folks ... Legalities have to be respected ... However I wouldn't want to be out of this over the weekend ... :0) ... LH&K Mafuta
I am still feeling extremely confident even though we still have radio silence as ...
1 - TM added ENGLAND to his directorship details ... to me that was an exercise to align all paperwork (i's and t's)
2 - S Parker picked up a new job ... i know he has bandwidth but the timing seems right if we are close to a T/O
3 - Many pieces of RNS all seemingly arriving slower than we would like ... GSK/Sierra Ackt .... Mid Year Report ... CTA progress ...
All the silence IMHO implies major discussions behind the scenes ... or that is my hope and now that the GSK deal is done I expect fireworks shortly .. lets see
Good luck to all holders ;
Confirmation is tomorrow so still a little time to wait
I tweeted regarding updates to Parker and it was taken down
Be patient there is definitely news coming soon